0
Bicycle Therapeutics plc Banner Image

Bicycle Therapeutics plc

  • Ticker BCYC
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Bicycle Therapeutics plc Logo Image
  • 51-200 Employees
  • Based in Cambridge, Cambridgeshire
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target bindingMore with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA.
Bicycle Therapeutics plc

Most Recent Annual Report

Bicycle Therapeutics plc
MOST RECENT 2021 Annual Report and Form 10K

Older/Archived Annual Reports